Targeting adenosine signaling to treatment of diabetic nephropathy

Current Drug Targets

Volumn 14, Issue 4, 2013, Pages 490-496

  Quezada, Claudia ^a   Alarcón, Sebastián ^a   Jaramillo, Catherinne ^a   Muñoz, Daniel ^b   Oyarzún, Carlos ^a   Martín, Rody San ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^b UNIVERSIDAD DIEGO PORTALES   (Chile)

Author keywords

Adenosine; Adenosine A2B receptor; Diabetic nephropathy; Equilibrative nucleoside transporters

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; AUTOTAXIN; CYCLIC AMP; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; PROTEIN KINASE C; VASCULOTROPIN;

DIABETIC NEPHROPATHY; DISEASE COURSE; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGENICITY; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY INJURY; MACULA DENSA; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SEVERE COMBINED IMMUNODEFICIENCY; VASODILATATION;

ADENOSINE; ANIMALS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; RECEPTOR, ADENOSINE A2B; SIGNAL TRANSDUCTION;

EID: 84876712864     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314040010     Document Type: Review

References (114)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40.
2. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49: S12-S154.
3. De Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305: 2532-9.
4. Gross ML, Dikow R, Ritz E. Diabetic nephropathy: recent insights into the pathophysiology and the progression of diabetic nephropathy. Kidney Int 2005; 94: S50-3.
5. Ardiles L, Mezzano S. Diabetic renal disease: the World Kidney Day in Chile. Rev Med Chil 2010; 138: 397-400.
6. Barceló A, Aedo C, Rajpathak S, et al. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ 2003; 81: 19-27.
7. ADA. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33(suppl 1): S11-S61.
8. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-91.
9. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-51.
10. Ardiles LG, Poblete H, Ortiz M, et al. The health system in Chile: the nephrologist perspective. J Nephrol 2011; 24: 149-54.
11. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: US Renal Data System 2010. Available at: http://www.usrds.org/2010/view/v1_00a_intro.asp
12. Chavers BM, Bilous RW, Ellis EN, et al. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med 1989; 320: 966-70.
13. Mogensen CE. Early glomerular hyperfiltration in insulindependent diabetics and late nephropathy. Scand J Clin Lab Invest 1986; 46: 201-206.
14. Nath KA. The tubulointerstitium in progressive renal disease. Kidney Int 1998; 54: 992-4.
15. Coward R, Saleem M. Podocytes as a Target of Insulin. Curr Diabetes Rev 2011; 7: 22-27.
16. Welsh GI, Hale LJ, Eremina V, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010; 12: 329-40.
17. Orchard TJ, Chang YF, Ferrell RE, et al. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 2002; 62: 963-70.
18. Yki-Järvinen H and Koivisto VA. Natural course of insulin resistance in type I diabetes. N Engl J Med 1986; 315: 224-30.
19. Mogensen CE, Christensen NJ, Gundersen HJ. The acute effect of insulin on heart rate, blood pressure, plasma noradrenaline and urinary albumin excretion. The role of changes in blood glucose. Diabetologia 1980; 18: 453-7.
20. Bianchi S, Bigazzi R, Quinones-Galvan A, et al. Insulin resistance in microalbuminuric hypertension. Sites and mechanisms. Hypertension 1995; 26: 789-95.
21. Jager A, Kostense P, Nijpels G, et al. Microalbuminuria is strongly associated with NIDDM and hypertension but not with the insulin resistance syndrome. Diabetologia 1998; 41: 694-700.
22. Savage S, Estacio RO, Jeffers B, et al. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: A population study. Proc Assoc Am Physicians 1997; 109: 181-9.
23. Weitzman S, Maislos M, Bodner-Fishman B, et al. Association of diabetic retinopathy, ischemic heart disease, and albuminuria with diabetic treatment in type 2 diabetic patients. A population based study. Acta Diabetol 1997; 34: 275-9.
24. Rademacher E, Mauer M, Jacobs D Jr, et al. Albumin excretion rate in normal adolescents: Relation to insulin resistance and cardiovascular risk factors and comparisons to type 1 diabetes mellitus patients. Clin J Am Soc Nephrol 2008; 3: 998-1005.
25. Flyvbjerg A, Khatir DS, Jensen LJ, et al. The involvement of growth hormone (GH), insulin like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. Curr Pharm Des 2004; 10: 3385-94.
26. Uehara G, Suzuki D, Toyoda M, et al. Glomerular expression of platelet-derived growth factor (PDGF)-A,-B chain and PDGF receptor-alpha,-beta in human DN. Clin Exp Nephrol 2004; 8: 36-42.
27. Ziyadeh FN. Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res Clin Pract 2008; 82: S38-41.
28. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-25.
29. Nakagawa T, Sato W, Glushakova O, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007; 18: 539-50.
30. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of VEGF in renal pathophysiology. Kidney Int 2004; 65: 2003-17.
31. De Vriese A, Tilton R, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000.
32. Flyvbjerg A, Dagnaes-Hansen F, De Vriese A. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing VEGF antibody. Diabetes 2002; 51: 3090-4.
33. Liu E, Morimoto M, Kitajima S, et al. Increased expression of VEGF in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007; 18: 2094-104.
34. Veron D, Bertuccio C, Marlier A, et al. Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia 2011; 54: 1227-41.
35. Veron D, Reidy KJ, Bertuccio C, et al. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 2010; 77: 989-99.
36. Cha DR, Kim NH, Yoon JW, et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl 2000; 77: S104-12.
37. Gröne HJ, Simon M, Gröne EF. Expression of VEGF in renal vascular disease and renal allografts. J Pathol 1995; 177: 259-67.
38. Shulman K, Rosen S, Tognazzi K, et al. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 1996; 7: 661-6.
39. Kanesaki Y, Suzuki D, Uehara G, et al. VEGF gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 2005; 45: 288-9.
40. Mirkovic K, Van den Born J, Navis G, De Borst MH. Vitamin D in chronic kidney disease: new potential for intervention. Curr Drug Targets 2011; 12: 42-53.
41. Mironidou-Tzouveleki M, Tsartsalis S, Tomos C. Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus. Curr Drug Targets 2011; 12: 107-14.
42. De Borst MH. Vitamin D deficiency in cardiovascular and renal disease: new light shed on an old enemy. Curr Drug Targets 2011; 12: 1-3.
43. Holian J, Qi W, Kelly DJ, et al. Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells. Am J Physiol Renal Physiol 2008; 295: F1388-96.
44. Simonson MS. Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int 2007; 71: 846-54.
45. Mezzano S, Droguett A, Burgos ME, et al. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl 2003; 86: S64-70.
46. Wassef L, Langham RG, Kelly DJ. Vasoactive renal factors and the progression of diabetic nephropathy. Curr Pharm Des 2004; 10: 3373-84.
47. Fredholm B, IJzerman A, Jacobson K, et al. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors-An Update. Pharmacol Rev 2011; 63: 1-34.
48. Huang DY, Vallon V, Zimmermann H, Koszalka P, Schrader J, Osswald H. Ecto-5'-nucleotidase (cd73)-dependent and-independent generation of adenosine participates in the mediation of tubuloglomerular feedback in vivo. Am J Physiol Renal Physiol 2006; 291: F282-8.
49. Brown R, Ollerstam A, Johansson B, et al. Abolished tubuloglomerular feedback and increased plasma renin in adenosine A1 receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1362-7.
50. Kim S, Mizel D, Huang Y, Briggs J, Schnermann J. Adenosine as a mediator of macula densa-dependent inhibition of renin secretion. Am J Physiol Renal Physiol 2006; 290: F1016-23.
51. Wei Y, Sun P, Wang Z, Yang B, Carroll M, Wang W. Adenosine inhibits ENaC via cytochrome P-450 epoxygenase-dependent metabolites of arachidonic acid. Am J Physiol Renal Physiol 2006; 290: F1163-8.
52. Churchill P, Churchill M. A1 and A2 adenosine receptor activation inhibits and stimulates renin secretion of rat renal cortical slices. J Pharmacol Exp Ther 1985; 232: 589-94.
53. Hansen P, Schnermann J. Vasoconstrictor and vasodilator effects of adenosine in the kidney. Am J Physiol Renal Physiol 2003; 285: F590-9.
54. Wengert M, Berto C Jr, Kaufman J, et al. Stimulation of the proximal tubule Na+-ATPase activity by adenosine A2A receptor. Int J Biochem Cell Biol 2005; 37: 155-65.
55. Zhao Z, Kapoian T, Shepard M, Lianos EA. Adenosine-induced apoptosis in glomerular mesangial cells. Kidney Int 2002; 61: 1276-85.
56. Jackson EK, Gillespie DG, Dubey RK. 2'-AMP and 3'-AMP inhibit proliferation of preglomerular vascular smooth muscle cells and glomerular mesangial cells via A2B receptors. J Pharmacol Exp Ther 2011; 337: 444-50.
57. Grenz A, Bauerle JD, Dalton JH, et al. Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest 2012; 122: 693-710.
58. Jackson EK, Dubey RK. The extracellular cyclic AMP-adenosine pathway in renal physiology. Annu Rev Physiol 2004; 66: 571-99.
59. Shirley DG, Vekaria RM, Sévigny J. Ectonucleotidases in the kidney. Purinergic Signal 2009; 5: 501-11.
60. Castrop H, Huang Y, Hashimoto S, et al. Impairment of tubuloglomerular feedback regulation of GFR in ecto-5'-nucleotidase/CD73-deficient mice. J Clin Invest 2004; 114: 634-42.
61. Jackson EK, Mi Z, Zhu C, Dubey RK. Adenosine biosynthesis in the collecting duct. J Pharmacol Exp Ther 2003; 307: 888-96.
62. Jackson EK, Zacharia LC, Zhang M, Gillespie DG, Zhu C, Dubey RK. cAMP-adenosine pathway in the proximal tubule. J Pharmacol Exp Ther 2006; 317: 1219-29.
63. San Martín R, Valladares D, Roa H, et al. Do adenosine receptors offer new therapeutic options for diabetic nephropathy?. Curr Vasc Pharmacol 2009; 7: 450-9.
64. Riksen NP, Rongen GA, Boers GH, et al. Enhanced cellular adenosine uptake limits adenosine receptor stimulation in patients with hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 2005; 25: 109-114.
65. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an ENT by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 2006; 103: 7895-900.
66. Roa H, Gajardo C, Troncoso E, et al. Adenosine mediates transforming growth factor-beta 1 release in kidney glomeruli of diabetic rats. FEBS Lett 2009; 583: 3192-8.
67. Choi DS, Cascini MG, Mailliard W, et al. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat Neurosci 2004; 7: 855-61.
68. Antonioli L, Colucci R, La Motta C, et al. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr Drug Targets 2012; 13: 842-62.
69. Sakowicz M, Szutowicz A, Pawelczyk T. Insulin and glucose induced changes in expression level of nucleoside transporters and adenosine transport in rat T lymphocytes. Biochem Pharmacol 2004; 68: 1309-20.
70. Farías M, San Martín R, Puebla C, et al. Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol 2006; 208: 451-60.
71. Aguayo C, Casado J, Gonzalez M, et al. Equilibrative Nucleoside Transporter 2 is Expressed in Human Umbilical Vein Endothelium, But is not Involved in the Inhibition of Adenosine Transport Induced by Hyperglycaemia. Placenta 2005; 26: 641-53.
72. Young JD, Yao SY, Sun L, Cass CE, Baldwin SA. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 2008; 38: 995-1021.
73. Baldwin SA, Yao SY, Hyde RJ, et al. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 2005; 280: 15880-7.
74. Ricci Z, Ronco C. Pathogenesis of acute kidney injury during sepsis. Curr Drug Targets 2009; 10: 1179-83.
75. Pelte CH, Chawla LS. Novel therapeutic targets for prevention and therapy of sepsis associated acute kidney injury. Curr Drug Targets 2009; 10: 1205-11.
76. Rosner MH. Acute kidney injury: turning the tide. Curr Drug Targets 2009; 10: 1165-8.
77. Liu KD, Glidden DV. Clinical trials for acute kidney injury: design challenges and possible solutions. Curr Drug Targets 2009; 10: 1190-5.
78. Cárdenas A, Toledo C, Oyarzún C, et al. Adenosine A2B receptormediated VEGF induction promotes diabetic glomerulopathy. Lab Invest 2013; 93(1): 135-44.
79. Xia JF, Liang QL, Liang XP, et al. Ultraviolet and tandem mass spectrometry for simultaneous quantification of 21 pivotal metabolites in plasma from patients with diabetic nephropathy. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1930-6.
80. Dai Y, Zhang W, Wen J, Zhang Y, Kellems RE, Xia Y. A2B adenosine receptor-mediated induction of IL-6 promotes CKD. J Am Soc Nephrol 2011; 22: 890-901.
81. Pawelczyk T, Podgorska M, Sakowicz M. The effect of insulin on expression level of nucleoside transporters in diabetic rats. Mol Pharmacol 2003; 63: 81-8.
82. Angielski S, Jakubowski Z, Pawelczyk T, Piec G, Redlak M. Renal handling and metabolism of adenosine in diabetic rats. Contrib Nephrol 1989; 73: 52-7.
83. Karczewska J, Martyniec L, Dzierzko G, et al. The relationship between constitutive ATP release and its extracellular metabolism in isolated rat kidney glomeruli. J Physiol Pharmacol 2007; 58: 321-33.
84. Westermeier F, Salomón C, González M, et al. Insulin restores gestational diabetes mellitus-reduced adenosine transport involving differential expression of insulin receptor isoforms in human umbilical vein endothelium. Diabetes 2011; 60: 1677-87.
85. Muñoz G, San Martín R, Farías M, et al. Insulin restores glucose inhibition of adenosine transport by increasing the expression and activity of the equilibrative nucleoside transporter 2 in human umbilical vein endothelium. J Cell Physiol 2006; 209: 826-35.
86. Karczewska J, Piwkowska A, Rogacka D, Ste{ogonek}piński J, Angielski S, Jankowski M. Purinergic modulation of glucose uptake into cultured rat podocytes: effect of diabetic milieu. Biochem Biophys Res Commun 2011; 404: 723-7.
87. Awad A, Huang L, Ye H, et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F828-37.
88. Vallon V, Schroth J, Satriano J, et al. Adenosine A1 receptors determine glomerular hyperfiltration and the salt paradox in early STZ diabetes mellitus. Nephron Physiol 2009; 111: 30-8.
89. Faulhaber-Walter R, Chen L, Oppermann M, et al. Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury. J Am Soc Nephrol 2008; 19: 722-30.
90. Pawelczyk T, Grden M, Rzepko R, Sakowicz M, Szutowicz A. Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am J Pathol 2005; 167: 315-25.
91. Hoshi S, Nomoto K, Kuromitsu J, et al. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun 2002; 290: 177-84.
92. Lee EY, Chung CH, Kim JH, et al. Antioxidants ameliorate the expression of vascular endothelial growth factor mediated by protein kinase C in diabetic podocytes. Nephrol Dial Transplant 2006; 21: 1496-503.
93. Valladares D, Quezada C, Montecinos P, Concha II, Yañez AJ, Sobrevia L, San Martín R. Adenosine A2B receptor mediates an increase on VEGF-A production in rat kidney glomeruli. Biochem Biophys Res Commun 2008; 366: 180-5.
94. Yoo TH, Li JJ, Kim JJ, et al. Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007; 71: 1019-27.
95. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: F477-F486.
96. Zimpelmann J, Kumar D, Levine DZ, et al. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 2000; 58: 2320-33.
97. Singh R, Singh AK, Alavi N, et al. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 2003; 14: 873-80.
98. Vidotti DB, Casarini DE, Cristovam PC, et al. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol 2004; 286: F1039-F1045.
99. Lin CL, Wang FS, Hsu YC, et al. Modulation of notch-1 signaling alleviates vascular endothelial growth factor-mediated diabetic nephropathy. Diabetes 2010; 59: 1915-25.
100. Sun CX, Zhong H, Mohsenin A, et al. Role of A2B adenosine receptor signaling in adenosine dependent pulmonary inflammation and injury. J Clin Invest 2006; 116: 2173-82.
101. Peng Z, Fernandez P, Wilder T, et al. Ecto-5'-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis. FASEB J 2008; 22: 2263-72.
102. Figler RA, Wang G, Srinivasan S, et al. Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes 2011; 60: 669-79.
103. Xia JF, Liang QL, Hu P, et al. Correlations of six related purine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients. Clin Biochem 2009; 42: 215-20.
104. Booth C; Gaspar HB. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics, 2009; 3: 349-58.
105. Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987; 316: 589-96.
106. Abuchowski A, McCoy JR, Palczuk NC, et al. Effect of covalent attachment of PEG on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977; 252: 3582-6.
107. Davis S, Abuchowski A, Park YK, et al. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol 1981; 46: 649-52.
108. Wen J, Jiang X, Dai Y, et al. Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism. J Sex Med 2010; 7: 3011-22.
109. Guillén-Gómez E, Pinilla-Macua I, Pérez-Torras S, et al. New Role of hENT1 in Epithelial-to-Mesenchymal Transition in Renal Tubular Cells. J Cell Physiol 2012; 227: 1521-8.
110. Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005; 16: 1404-12.
111. Kramer HJ, Nguyen QD, Curhan G, et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289: 3273-7.
112. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 2003; 52: 1036-40.
113. Retnakaran R, Cull CA, Thorne KI, et al. UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-9.
114. Costacou T, Ellis D, Fried L, et al. Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. Am J Kidney Dis 2007; 50: 721-32.